Reuters logo
BRIEF-Paratek announces completion of enrollment in Omadacycline phase 3 community-acquired bacterial pneumonia study
January 18, 2017 / 12:22 PM / a year ago

BRIEF-Paratek announces completion of enrollment in Omadacycline phase 3 community-acquired bacterial pneumonia study

Jan 18 (Reuters) - Paratek Pharmaceuticals Inc

* Paratek announces completion of enrollment in Omadacycline phase 3 community-acquired bacterial pneumonia study

* Paratek Pharmaceuticals Inc says company expects to report top-line data from this study in Q2 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below